Key Takeaways
- •ObesityWeek 2026 is scheduled for November 1-5, according to early meeting information, and the semaglutide conference presentation slate is expected to anchor much of the program.
- •Semaglutide and tirzepatide are the two drugs with the most established clinical footprints heading into the meeting.
- •A second, smaller conference focused on peptide therapeutics is also on the calendar for September 21-23, covering stapled peptides, cyclic peptides, cell-penetrating peptides, and next-generation peptide drug design.
ObesityWeek 2026 Is Coming, and the GLP-1 Pipeline Is Crowded
ObesityWeek 2026 is scheduled for November 1-5, according to early meeting information, and the semaglutide conference presentation slate is expected to anchor much of the program. The meeting has become the central venue for late-stage obesity and metabolic disease data, and this year arrives with an unusually deep bench of compounds competing for attention.
Semaglutide and tirzepatide are the two drugs with the most established clinical footprints heading into the meeting. Both are verified as active compounds in the current research and commercial landscape. Around them sits a broader pipeline that includes retatrutide, survodutide, and cagrilintide, each of which has been reported as an investigational candidate in industry and academic disclosures.
A second, smaller conference focused on peptide therapeutics is also on the calendar for September 21-23, covering stapled peptides, cyclic peptides, cell-penetrating peptides, and next-generation peptide drug design. That meeting speaks to the chemistry side of the field, while ObesityWeek covers the clinical and regulatory side.
What to Watch at ObesityWeek 2026
The headline sessions will likely center on semaglutide and tirzepatide, the two compounds with the largest body of published data. Researchers tracking the field should expect updated analyses on weight loss durability, cardiovascular endpoints, and tolerability across different patient populations.
Beyond the two market leaders, the more interesting question is how the next wave positions itself. Retatrutide, survodutide, and cagrilintide have all been discussed as candidates with distinct mechanisms or combination strategies. According to early reports, some of these programs are advancing through mid- and late-stage trials, though the specific data readouts expected at the meeting have not been confirmed.
Novo Nordisk and Boehringer Ingelheim are both reportedly involved in the broader obesity and metabolic research space, and their presence at major conferences tends to shape which datasets get the most attention. Novo Nordisk is associated with semaglutide across its Ozempic, Wegovy, and Rybelsus formulations, while Boehringer Ingelheim has been linked to survodutide development.
The Regulatory Timeline Is Moving in Parallel
Conference data does not exist in a vacuum. The FDA is reportedly reviewing or monitoring several of these programs, and the timing of presentations often aligns with regulatory milestones. A date of December 5 has been referenced in early scheduling information, though what it corresponds to has not been confirmed.
For researchers, the practical takeaway is that ObesityWeek 2026 will function as both a scientific meeting and a preview of what regulators will see in the months that follow. Presentations on semaglutide and tirzepatide will inform clinical practice discussions, while data on retatrutide, survodutide, and cagrilintide will shape how the next generation of compounds is positioned.
If you are tracking how these compounds are studied at the bench level, Volta Peptides maintains a peptide glossary that covers the core terminology, and our research blog regularly digests new findings across the field.
Why the Peptide Chemistry Meeting Matters Too
The September 21-23 peptide therapeutics conference is a different kind of event. It focuses on the engineering problems that determine whether a promising sequence becomes a viable drug: stapled peptides for stability, cyclic peptides for binding affinity, and cell-penetrating peptides for delivery.
These are the same challenges that apply to the GLP-1 class, even if the clinical meetings rarely frame them that way. Semaglutide and tirzepatide are not simple molecules. Their behavior depends on modifications that improve half-life, reduce degradation, and allow for practical dosing schedules. The chemistry meeting is where those design decisions get discussed in detail.
For researchers working with peptides in a lab setting, tools like the peptide half-life calculator and the stability calculator can help translate some of these design principles into practical experimental planning.
What This Means for the Research Community
ObesityWeek 2026 will not settle the obesity drug debate, but it will clarify where the field stands. Semaglutide and tirzepatide have set a high bar. Retatrutide, survodutide, and cagrilintide are among the candidates being watched to see whether they can clear it, and on what dimensions: greater weight loss, better tolerability, or improved cardiovascular outcomes.
The September peptide therapeutics meeting adds a complementary layer. Advances in stapled peptides, cyclic peptides, and cell-penetrating peptides do not make headlines the way phase 3 weight loss data does, but they determine what kinds of molecules are possible in the next decade.
Researchers planning to follow both meetings should keep an eye on Volta Peptides news for updates as presentation schedules are confirmed. For those working with reconstituted compounds in the lab, the reconstitution calculator remains a useful reference for accurate preparation.
Related Research Compounds
Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.
| Compound | Purity | Size | Price |
|---|---|---|---|
| Semaglutide 10mg | ≥98% | 10mg | $49.00 |
| Retatrutide 20mg | ≥98% | 20mg | $99.00 |
| Tirzepatide 10mg | ≥98% | 10mg | $34.00 |
| Retatrutide 10mg | ≥98% | 10mg | $64.00 |
FAQ
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist that is verified as an active compound in the current obesity and diabetes research landscape. It is associated with the Ozempic, Wegovy, and Rybelsus product lines and is expected to be a major focus of ObesityWeek 2026 presentations.
Is semaglutide safe?
Safety is evaluated through clinical trials and post-market surveillance. Semaglutide has an established clinical footprint, and updated safety analyses are typically presented at major conferences. Anyone with specific safety questions should consult the primary literature and regulatory communications rather than conference summaries alone.
What is tirzepatide?
Tirzepatide is a verified active compound in the obesity and metabolic disease space and is one of the two drugs with the largest body of clinical data heading into ObesityWeek 2026. Like semaglutide, it is expected to feature prominently in the meeting's scientific program.
